azd9164
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT00847249)
Timeline
Indications
Mechanism of action
- Muscarinic acetylcholine receptor M1ANTAGONIST
CHRM1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd9164
- azd9164
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01096563 | Phase 1 | Mar 1, 2010 | AstraZeneca, Richmond Pharmacology |
| NCT01016951 | Phase 1 | Dec 1, 2009 | AstraZeneca, IQVIA |
| NCT00939211 | Phase 2 | Jun 1, 2009 | AstraZeneca, Lund University |
| NCT00847249 | Phase 1 | Feb 1, 2009 | AstraZeneca, Lund University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 4 | 4 | 2 | 2009 |
| Lund University | Academic/Hospital | 2 | 0 | 2 | 2009 |
| IQVIA | For profit | 1 | 0 | 1 | 2009 |
| Richmond Pharmacology | For profit | 1 | 0 | 1 | 2010 |
4 organizations
Page 1 / 1